Wyeth’s TORISEL Receives European Commission Approval For The Treatment Of Advanced Kidney Cancer

November 27th, 2007 | Category: Cancer

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced that the European Commission has approved TORISEL(TM) (temsirolimus) for the first-line treatment of patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors. TORISEL is the only

approved cancer therapy that specifically inhibits the mTOR (mammalian target of rapamycin) kinase, an urgent regulator of cell proliferation, cell growth and cell survival. [click link for full article]

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Wyeth Initiates INTORACT — A New Clinical Trial To Examine TORISEL Plus Avastin For First-Line Treatment Of Advanced Kidney Cancer
  • European Committee Issues Positive Opinion On Wyeth’s TORISEL For Advanced Renal Cell Carcinoma
  • New Breakthrough Treatment For Advanced Kidney Cancer Shows 49 Per Cent Higher Survival Rates
  • Aclasta(R) Receives European Approval As First Once-yearly Treatment For Postmenopausal Osteoporosis
  • Aclasta Receives European Approval As First Once Yearly Treatment For Postmenopausal Osteoporosis

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.